ArticleJournal of functional biomaterials2026
Biocompatible Germanium-Enriched Nanocomposite Coatings on Titanium Designed Toward Preventing Early Inflammation and Promoting Osteogenic Differentiation.
Article in Journal of functional biomaterials, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
The study seeks to develop a multifunctional germanium-enriched nanocomposite coating on titanium and to evaluate its ability to modulate early inflammatory responses while promoting osteogenic differentiation in a dental pulp stem cell (DPSC)-based regenerative model. A multifunctional Ti/Coating composed of nanohydroxyapatite (nHAp) particles, chitosan-oligolactate (ChOL), and germanium (Ge) was developed using a combined anodizing/anaphoretic electrodeposition approach. The Ti/Coating system exhibited good biocompatibility, as confirmed by microscopy, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) and lactate dehydrogenase (LDH) assays, with cell viability consistently exceeding 90% and moderate LDH release across all time points. Annexin V/PI assay demonstrated a predominance of viable cells (>94%), while intracellular ROS analysis indicated moderate oxidative activity. Gene expression analysis revealed significant downregulation of pro-inflammatory markers (
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.